Literature DB >> 11158745

Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

A Louie1, P Kaw, P Banerjee, W Liu, G Chen, M H Miller.   

Abstract

In vitro time-kill studies and a rabbit model of endocarditis and pyelonephritis were used to define the impact that the order of exposure of Candida albicans to fluconazole (FLC) and amphotericin B (AMB), as sequential and combination therapies, had on the susceptibility of C. albicans to AMB and on the outcome. The contribution of FLC-induced resistance to AMB for C. albicans also was assessed. In vitro, AMB monotherapy rapidly killed each of four C. albicans strains; FLC alone was fungistatic. Preincubation of these fungi with FLC for 18 h prior to exposure to AMB decreased their susceptibilities to AMB for 8 to >40 h. Induced resistance to AMB was transient, but the duration of resistance increased with the length of FLC preincubation. Yeast sequentially incubated with FLC followed by AMB plus FLC (FLC-->AMB+FLC) showed fungistatic growth kinetics similar to that of fungi that were exposed to FLC alone. This antagonistic effect persisted for at least 24 h. Simultaneous exposure of C. albicans to AMB and FLC [AMB+FLC(simult)] demonstrated activity similar to that with AMB alone for AMB concentrations of > or =1 microg/ml; antagonism was seen using an AMB concentration of 0.5 microg/ml. The in vitro findings accurately predicted outcomes in our rabbit infection model. In vivo, AMB monotherapy and treatment with AMB for 24 h followed by AMB plus FLC (AMB-->AMB+FLC) rapidly sterilized kidneys and cardiac vegetations. AMB+FLC(simult) and FLC-->AMB treatments were slower in clearing fungi from infected tissues. FLC monotherapy and FLC-->AMB+FLC were both fungistatic and were the least active regimens. No adverse interaction was observed between AMB and FLC for the AMB-->FLC regimen. However, FLC-->AMB treatment was slower than AMB alone in clearing fungi from tissues. Thus, our in vitro and in vivo studies both demonstrate that preexposure of C. albicans to FLC reduces fungal susceptibility to AMB. The length of FLC preexposure and whether AMB is subsequently used alone or in combination with FLC determine the duration of induced resistance to AMB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158745      PMCID: PMC90317          DOI: 10.1128/AAC.45.2.485-494.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

2.  Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits.

Authors:  D T Durack; P B Beeson; R G Petersdorf
Journal:  Br J Exp Pathol       Date:  1973-04

3.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

4.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Discrepant results of amphotericin B assays on fresh versus frozen serum samples.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

6.  Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.

Authors:  E Martin; F Maier; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Interactions in vitro between polyenes and imidazoles against yeasts.

Authors:  M A Petrou; T R Rogers
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

8.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

9.  Indications for therapy for fungemia in postoperative patients.

Authors:  J S Solomkin; A M Flohr; R L Simmons
Journal:  Arch Surg       Date:  1982-10

10.  Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid.

Authors:  J H Jorgensen; G A Alexander; J R Graybill; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

View more
  15 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Dominique Sanglard; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 4.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

Authors:  Anthony Cacciapuoti; Maya Gurnani; Judith Halpern; Christine Norris; Reena Patel; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 6.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Fungal Endocarditis.

Authors:  Eyal Nadir; Ethan Rubinstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

8.  Competitive binding inhibition enzyme-linked immunosorbent assay that uses the secreted aspartyl proteinase of Candida albicans as an antigenic marker for diagnosis of disseminated candidiasis.

Authors:  Christine J Morrison; Steven F Hurst; Errol Reiss
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

9.  Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.

Authors:  Manjunath P Pai; Marie L Samples; Renee-Claude Mercier; Michael N Spilde
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

10.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.